Introduction
Retinopathy of prematurity is treated with careful monitoring, supplemental oxygen management, laser photocoagulation, anti-VEGF injection therapy, and in advanced cases surgery such as vitrectomy or scleral buckling. These treatments are used to control the abnormal growth of retinal blood vessels, limit retinal damage, and prevent progression to retinal detachment or permanent vision loss. The overall treatment strategy is based on the biology of the developing retina: when premature birth interrupts normal vessel growth, the retina may become relatively oxygen deprived and release signals that drive fragile, disorganized neovascularization. Treatment aims to interrupt that process, stabilize retinal structure, and preserve visual function.
Understanding the Treatment Goals
The main goals of treatment for retinopathy of prematurity are to prevent disease progression, reduce the risk of retinal detachment, and preserve usable vision. Because the disorder arises from abnormal vascular development rather than a primary infection or inflammation, treatment is directed at the vascular response of the immature retina. The first goal is to identify infants at risk early enough that intervention can occur before the retina enters the most destructive stages. The second goal is to suppress the signals that stimulate pathologic vessel growth or to destroy the peripheral avascular retina that produces those signals. The third goal is to maintain the anatomical relationship between the retina and the underlying tissues so that retinal function can continue normally.
Treatment decisions are guided by the stage of the disease, the zone of retinal involvement, and whether there are signs of progression such as plus disease, in which retinal vessels become dilated and tortuous because of increased vascular activity. A treatment is chosen when the risk of progression outweighs the risks of intervention. In milder cases, close observation may be sufficient because the retina can continue normal vascularization without active treatment. In more advanced disease, intervention is needed because the pathological process can permanently distort the retinal architecture.
Common Medical Treatments
The most established medical treatment for retinopathy of prematurity is laser photocoagulation. In this procedure, the avascular peripheral retina is treated with laser energy, which destroys the tissue that is producing high levels of vascular growth signals such as vascular endothelial growth factor, or VEGF. In a developing eye, the peripheral retina that lacks blood supply becomes hypoxic and stimulates abnormal vessel proliferation. Laser treatment reduces this biochemical drive by ablating the oxygen-starved tissue. The procedure does not restore already lost retina, but it changes the local environment so that pathologic blood vessel growth slows or stops.
Anti-VEGF therapy is another major treatment approach. It involves injection of a medication into the eye that blocks VEGF, the key molecule that promotes new vessel growth and leakage. In retinopathy of prematurity, VEGF is central to the abnormal angiogenic response that occurs when the retina is incompletely vascularized. By neutralizing this signal, anti-VEGF agents reduce neovascular activity, lessen vascular leakage, and can allow the retinal vessels to mature in a more controlled pattern. This treatment is especially useful in certain posterior forms of the disease where laser treatment may be less effective or more damaging to central vision. Its mechanism is biologically targeted: rather than destroying tissue, it alters the molecular signals that drive disease progression.
Supplemental oxygen management is also part of treatment, although it functions differently from laser or anti-VEGF therapy. Oxygen therapy is carefully controlled in premature infants because both excess oxygen and oxygen instability can influence retinal vessel development. High oxygen levels early in life can suppress normal vessel growth, while later fluctuations in oxygen tension can contribute to the abnormal angiogenic phase. Clinical oxygen management attempts to keep systemic oxygen within a range that supports survival while minimizing retinal vascular injury. This approach does not treat existing lesions directly, but it addresses a major physiological factor that shapes disease development.
Procedures or Interventions
Procedural intervention is used when the disease reaches a threshold where observation is no longer safe. Laser photocoagulation is the most common procedure for threshold or high-risk pre-threshold disease. It is usually applied to the peripheral retina because that region is not yet vascularized in affected infants. By destroying the peripheral ischemic tissue, the procedure reduces retinal production of pro-angiogenic mediators. The result is a lower stimulus for abnormal neovascularization, helping the remaining retina avoid tractional distortion.
Anti-VEGF injection is performed when rapid suppression of abnormal vessel activity is needed or when the anatomy of the disease makes laser difficult. The medication diffuses through the eye and binds VEGF, reducing the ability of this growth factor to signal through endothelial receptors. This can cause regression of abnormal vessels and reduce active leakage into the retina or vitreous. Because the retina remains biologically active after injection, follow-up is essential; vessel growth may resume as the drug level declines, and treatment may need to be repeated or supplemented with laser later.
In advanced retinopathy of prematurity, surgery may be necessary. If retinal traction has led to partial or total detachment, procedures such as scleral buckling or vitrectomy can be used. Scleral buckling works by indenting the wall of the eye to reduce the traction pulling on the retina. Vitrectomy removes the vitreous gel and fibrous membranes that are exerting traction on the retina, allowing the retina to be repositioned or reattached. These surgeries address the mechanical consequences of long-standing disease rather than the vascular trigger itself. Their purpose is to restore retinal anatomy when abnormal vascular proliferation has progressed to scar formation and tractional detachment.
Supportive or Long-Term Management Approaches
Supportive management is central to retinopathy of prematurity because the disease is dynamic and can change over time. Regular retinal examinations allow clinicians to detect the transition from immature vascular development to active disease and to determine when intervention is necessary. This surveillance works by identifying structural and vascular changes before irreversible damage occurs. Because the disease can regress spontaneously in some infants, follow-up also helps avoid unnecessary treatment while still catching progression early.
Long-term management may include repeated eye examinations even after acute treatment has been completed. This is particularly relevant after anti-VEGF therapy because retinal vascularization may continue in an unpredictable pattern and late recurrence can occur. In addition, children who have had retinopathy of prematurity may develop refractive errors, strabismus, amblyopia, or other visual sequelae that require ongoing ophthalmic care. These later problems arise because early vascular disturbance can alter retinal development, eye growth, and the maturation of visual pathways. Long-term monitoring therefore addresses both the original disease and its developmental consequences.
Systemic neonatal care also influences retinal outcomes. Stable respiratory support, avoidance of wide oxygen fluctuations, nutrition that supports growth, and management of other prematurity-related illnesses all affect the infant’s ability to complete normal retinal vascularization. These measures do not directly reverse retinopathy, but they help create a physiological environment in which the retina is less likely to continue abnormal angiogenic signaling.
Factors That Influence Treatment Choices
Treatment selection depends first on the stage and zone of the disease. Early stages may not require active intervention because the abnormal vascular response has not yet become severe enough to threaten the retina. More advanced stages, or disease involving the posterior retina, are treated more aggressively because they carry a higher risk of progression and visual impairment. The presence of plus disease also matters because it signals active vascular instability and a stronger drive toward abnormal neovascular growth.
The infant’s overall medical condition also influences treatment. Extremely ill premature infants may not tolerate some procedures as well as others, and the timing of treatment must be balanced against systemic stability. If the eye anatomy makes laser difficult, anti-VEGF therapy may be chosen because it can be delivered quickly and can be effective in posterior disease. If there is already traction or detachment, surgery becomes necessary because medical therapy cannot reverse fibrous pulling forces once scar tissue has formed.
Response to earlier treatment is another major factor. Some infants respond well to a single intervention, while others require repeat treatment or combined approaches. For example, anti-VEGF therapy may suppress active disease but still leave areas of peripheral retina incompletely vascularized, which can later require laser. The choice of therapy therefore reflects both the current appearance of the retina and how the disease has behaved over time.
Potential Risks or Limitations of Treatment
Each treatment has limitations because retinopathy of prematurity reflects abnormal retinal development rather than a single reversible lesion. Laser therapy can preserve vision by reducing the angiogenic drive, but it permanently destroys peripheral retinal tissue. That tissue is already poorly vascularized in affected infants, yet its ablation reduces peripheral visual field and may affect retinal function to some degree. Laser can also be technically challenging in very small or unstable infants.
Anti-VEGF therapy has a different set of concerns. Because VEGF is also important in normal vascular development, blocking it can alter the maturation of retinal vessels and may have systemic effects if the medication enters the circulation. A major limitation is that the treatment suppresses abnormal vessels without eliminating the avascular retina that produced the disease signal in the first place. For that reason, recurrence or delayed vascularization can occur, requiring prolonged surveillance. The pharmacological effect can also vary by drug and dose, which complicates long-term planning.
Surgical treatment carries the risks inherent in intraocular procedures, including bleeding, infection, cataract formation, and failure to reattach the retina if the disease is too advanced. Surgery is most effective when there is a mechanical component that can still be corrected, but it cannot fully restore retinal tissue that has already been severely damaged by scarring or detachment. Supportive management also has limits, because careful monitoring can detect progression but cannot by itself stop active severe disease.
Conclusion
Retinopathy of prematurity is treated through a combination of observation, oxygen management, laser therapy, anti-VEGF treatment, and in advanced cases surgery. These approaches are not interchangeable; each addresses a different part of the disease process. Some reduce the hypoxic stimulus for abnormal vessel growth, some block the molecular signals that drive neovascularization, and others correct the tractional or detachment changes that result from scar formation. Long-term follow-up remains essential because the condition evolves as the infant grows and the retina matures. Overall, treatment works by interrupting the abnormal vascular biology of the premature retina and preventing that process from progressing to structural damage and permanent vision loss.